Leucine-rich repeat kinase 2, Cell Signaling Technology, 13046

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human Leucine-rich repeat kinase 2 and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 13 commercial research antibodies against human Leucine-rich repeat kinase 2 encoded by LRRK2.

The collection of antibodies was tested using A549 WT and LRRK2 KO cells in the applications WB (WT and KO cell lysates/25 µg protein), IP (WT cell lysate) and IF (WT and KO cells) according to YCharOS standard protocols (see reference).

In WB (1:200 ab dilution) 13046 detected a band of appr. 245 kDa in WT cell lysate not observed in KO cell lysate. Bands of lower molecular weight was observed in both genotypes. A band was also detected following IP (2 µg Ab used). This band was more intense than the corresponding band in input extract (4% of starting material). A band was detected in immunodepleted extract (4% of total unbound fraction), showing that the antibody does not completely deplete the antigen from the cell lysate. In IF (1:100 ab dilution) WT cells showed only slightly stronger staining intensity compared to KO cells.

We highly encourage other scientists to share their observations.